Art

J-GLOBAL ID：202102231002812649   Reference number：21A0093518

Management of medically inoperable and tyrosine kinase inhibitor-naieve early-stage lung adenocarcinoma with epidermal growth factor receptor mutations: a retrospective multi-institutional analysis

上皮増殖因子受容体変異を伴う医学的に手術不能およびチロシンキナーゼ阻害剤未投与早期肺腺癌の管理:後ろ向き多施設解析【JST・京大機械翻訳】

Author (24)： Sun Yuemei (Cancer Center, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China) ,  Sun Yuemei (North Sichuan Medical College, Nanchong, China) ,  Wu Mengwan (School of Medicine, University of Electronic Science and Technology of China, Chengdu, China) ,  Zhou Mingxiu (School of Medicine, University of Electronic Science and Technology of China, Chengdu, China) ,  Luo Xing (School of Medicine, University of Electronic Science and Technology of China, Chengdu, China) ,  Guo Yan (School of Medicine, University of Electronic Science and Technology of China, Chengdu, China) ,  Bai Hansong (School of Medicine, University of Electronic Science and Technology of China, Chengdu, China) ,  Zhang Zican (Cancer Center, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China) ,  Zhang Zican (North Sichuan Medical College, Nanchong, China) ,  Tian Wei (Cancer Center, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China) ,  Tian Wei (School of Medicine, University of Electronic Science and Technology of China, Chengdu, China) ,  Wang Xiaoshan (Cancer Center, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China) ,  Bai Yifeng (Cancer Center, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China) ,  Zhu Xueqiang (Cancer Center, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China) ,  Pan Haixia (Cancer Center, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China) ,  Deng Ying (Cancer Center, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China) ,  Hu Honglin (Cancer Center, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China) ,  Xia Jianling (Cancer Center, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China) ,  Hao Xinbao (Sino-America Cancer Center, Hainan Medical University, First Affiliated Hospital of Hainan Medical College, Haikou, China) ,  Han Liangfu (Cancer Center, BoaoEvergrande International Hospital, Qionghai, Haikou, China) ,  Wei Min (Cancer Center, Ziyang People’s Hospital, Ziyang, China) ,  Liu Yingyi (Dept of Radiation Oncology, Sichuan Friendship Hospital, Chengdu, Sichuan, China) ,  Zeng Ming (Cancer Center, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China) ,  Zeng Ming (School of Medicine, University of Electronic Science and Technology of China, Chengdu, China)
Material： BMC Cancer (Web)
Volume： 20  Issue： 1  Page： 1-9  Publication year： 2020 
JST Material Number： U7305A  ISSN： 1471-2407  Document type： Article
Article type： 原著論文  Country of issue： United Kingdom (GBR)  Language： ENGLISH (EN)

Abstract/Point： The clinical value of combined...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=21A0093518&from=J-GLOBAL&jstjournalNo=U7305A") }}

Thesaurus term： multivariate analysis ,  radioactive ray ,  non-small cell lung cancer ,  *EGF receptor
Semi thesaurus term： *肺腺癌 ,  *チロシンキナーゼ阻害剤 ,  全生存率 ,  EGFRチロシンキナーゼ阻害剤 ,  *手術不能 ,  無増悪生存率 , 【Automatic Indexing@JST】

Author keywords (5)： EGFR ,  Inoperable ,  Lung adenocarcinoma ,  Radiation therapy ,  TKI

JST classification (2)： Tumors(=neoplasms)of respiratory system  (GI04000G) ,  Drug therapy(=pharmacotherapy)for tumors  (GE03032C)

Reference (20)：

• CA Cancer J Clin; Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries; F Bray, J Ferlay, I Soerjomataram, RL Siegel, LA Torre, A Jemal; 68; 6; 2018; 1-31; 10.3322/caac.21492; citation_id=CR1
• Science.; EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy; JG Paez, PA Janne, JC Lee; 304; 5676; 2004; 1497-1500; 10.1126/science.1099314; citation_id=CR2
• Clin Cancer Res; Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers; S Dogan, R Shen, DC Ang; 18; 22; 2012; 6169-6177; 10.1158/1078-0432.CCR-11-3265; citation_id=CR3
• PLoS One; Spectrum of oncogenic driver mutations in lung adenocarcinomas from east Asian never smokers; C Li, R Fang, Y Sun; 6; 11; 2011; e28204; 10.1371/journal.pone.0028204; citation_id=CR4
• N Engl J Med; Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR; M Maemondo, A Inoue, K Kobayashi; 362; 25; 2010; 2380-2388; 10.1056/NEJMoa0909530; citation_id=CR5

Terms in the title (10)： 上皮増殖因子受容体 ,  変異 ,  医学 ,  手術不能 ,  チロシンキナーゼ阻害剤 ,  投与 ,  早期 ,  肺腺癌 ,  施設 ,  解析